Skye Bioscience, Inc. (SKYE)

NGM – Цена в реальном времени. Валюта: USD

0.68

-0.03 (-4.02%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.68

+0.00 (0.01%)

После закрытия: Jun 26, 2026, 7:38 PM EDT

20.05.2026

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments.

12.05.2026

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.

11.05.2026

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”

22.04.2026

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.

07.04.2026

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor.

02.04.2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study

11.03.2026

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

20.05.2026

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

12.05.2026

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

11.05.2026

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

22.04.2026

Skye Bioscience, Inc. (SKYE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Skye Bioscience, Inc. (SKYE)

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Search stocks

Skye Bioscience, Inc. (SKYE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Skye Bioscience, Inc. (SKYE)

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm